Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 1999

View Archived Issues

Neurohumoral factors as predictors of benefit from carvedilol in ischemic LVD

Effects of macrolide antibiotics on IL-8 release by eosinophils in asthma

Stage I of phase III Neutralase study completed

Theragyn improves long-term survival in ovarian cancer patients

Osiris starts clinical trials of hMSC product

Anika and Zimmer expand Orthovisc distribution agreement

Data on Diatide diagnostics presented at Society of Nuclear Medicine meeting

Two-step inactivation procedure eliminates blood-borne viruses in FANDHI

First results of phase I/II trial evaluating arsenic trioxide in CML presented in Barcelona

Sepracor annual report: six ICE pharmaceuticals advanced in the pipeline in 1998

New company focusing on cell transplantation in CNS diseases spun off from NeuroSearch

Axcan sells contraception and STD subsidiary to Istituto Pirri; focus now on gastroenterology

Corixa to acquire Ribi in merger transaction slated to close in September

Medarex identifies valid Bispecific antibody approach to lymphoma Rx

New Amgen compounds inhibit production of proinflammatory cytokines

MMP and TNF-alpha inhibitors developed at Darwin Discovery

Pegylated OB protein shows beneficial effects on plasma lipids and appetite in obese subjects

Imidazotriazinones synthesized at Bayer inhibit cGMP-PDE isozymes

Array BioPharma designs series of potent and selective tryptase inhibitors

Protein kinase inhibitors especially useful for cancer in development at BMS

SmithKline Beecham presents new enzyme inhibitors useful for treating atherosclerosis

Alpha1-adrenoceptor antagonists in early development at Ono

Japanese lab discloses inhibitors of STAT6 activation

SB's Avandia now available in U.S. pharmacies

Green tea extract stimulates energy expenditure in humans; potential implications for weight loss

E.U. regulatory authority recommends suspension for Trovan

Metabolic effects of trecadrine in obese rats

Novel Src tyrosine kinase inhibitor with potential in human bone loss

Rilutek has potential role in Rx of levodopa-induced dyskinesias in PD patients

Algene changes name to SignalGene to reflect new beginning

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...